Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
Vol. 106, No. 1, 2011, pp. 113-116
Bioline Code: oc11018
Full paper language: English
Document type: Short Communication
Document available free of charge
Memórias do Instituto Oswaldo Cruz, Vol. 106, No. 1, 2011, pp. 113-116
© Copyright © 2011 - Instituto Oswaldo Cruz - Fiocruz
Presence of maternal anti-HBs antibodies does not influence hepatitis B vaccine response in Brazilian neonates|
Junqueira, Ana Luiza N.; Tavares, Viviane R.; Martins, Regina M.B.; Frauzino, Kamilla V.; da Costa e Silva, Agabo M.; Rodrigues, Izolina M.X.; Minamisava, Ruth & Teles, Sheila A.
Recently, it was suggested that maternal hepatitis B surface antigen antibodies (anti-HBs) acquired transplacentally could play a negative role in newborn infants' immune response to the hepatitis B vaccine. We compared the hepatitis B virus (HBV) vaccine response in infants born to mothers previously vaccinated against HBV (n = 91) to infants born to mothers who were not previously vaccinated (n = 221). All newborn infants received three intramuscular doses (10 μg) of HBV vaccine (Butang®) at 0,1 and six months. The first dose was administered at the maternity hospital within 12 h of birth. The geometric mean titres of anti-HBs were not different among newborn infants born to mothers who were anti-HBs-negative (492.7 mIU/mL) and anti-HBs-positive (578.7 mIU/mL) (p = 0.38). Eight infants did not respond to the HBV vaccine. Of them, six were born to anti-HBs-negative mothers and two were born to mothers with anti-HBs titres less than 50 mlU/mL. Despite the mother's anti-HBs-positive status, our data show a good immunogenicity of the Brazilian HBV recombinant vaccine in neonates.
hepatitis B vaccine - newborn infants - antibody response
Alternative site location: http://memorias.ioc.fiocruz.br